ANN ARBOR, Mich., March 7, 2012 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic
DNA-based therapeutics and innovative disease-modifying medicines
for serious illnesses, announced today that Jeff Riley, the Company's Chief Executive
Officer, will present at the ROTH Capital Partners 24th Annual
Growth Stock Conference. The conference will be held March 11-14, 2012 at The Ritz Carlton in
Dana Point, CA. Mr. Riley will
present on Wednesday, March 14, 2012
at 2:30pm (PT).
A live webcast of Synthetic Biologics' presentation can be
accessed by logging onto the web at
http://wsw.com/webcast/roth26/syn/. After the presentation, a
replay will be archived and accessible for 14 days at the same
website.
ROTH Capital Partners, LLC
ROTH Capital Partners, LLC (ROTH) is a relationship-driven
investment bank focused on identifying growth opportunities for
corporate and institutional clients. As a full-service investment
bank, ROTH provides capital raising, M&A advisory, analytical
research, trading and market-making services. Headquartered in
Newport Beach, CA, ROTH is
privately-held and owned by its employees, and maintains offices
throughout the U.S., Hong Kong and
a Shanghai Representative Office.
For more information on ROTH, please visit www.roth.com.
About Synthetic Biologics, Inc.
Synthetic Biologics is a biotechnology company focused on the
development of synthetic DNA-based therapeutics and innovative
disease-modifying medicines for serious illnesses. Synthetic
Biologics is developing, or has partnered the development of,
product candidates to treat pulmonary arterial hypertension,
relapses in multiple sclerosis, cognitive dysfunction in multiple
sclerosis, fibromyalgia and amyotrophic lateral sclerosis (ALS).
For more information, please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
SOURCE Synthetic Biologics, Inc.